Last reviewed · How we verify
5% O2
At a glance
| Generic name | 5% O2 |
|---|---|
| Sponsor | The University of Hong Kong-Shenzhen Hospital |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Fatigue
- Hypertension
- Platelet count decreased
- Vomiting
- Constipation
- Lymphocyte count decreased
- Anemia
- Anorexia
- Abdominal pain
- Diarrhea
- Hypoalbuminemia
Key clinical trials
- Exercise and Carotid Artery Function in Metabolic Syndrome
- MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL (PHASE2)
- Impact of the Early Life Virome Development on Bronchopulmonary Dysplasia in Preterm Neonates
- Hand Perfusion and Pulse Oximetry Performance
- The Effect of Hypercapnia on Physiological Parameters During Short-term Breathing (NA)
- Variability of SpO2 Measurements Depending on the Choice of Finger for Sensor Placement (NA)
- General Anesthesia and General Anesthesia Combined With Thoracic Epidural Anesthesia (NA)
- Carbon Dioxide (CO2) Chemosensitivity and SUDEP (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5% O2 CI brief — competitive landscape report
- 5% O2 updates RSS · CI watch RSS
- The University of Hong Kong-Shenzhen Hospital portfolio CI